Momentum builds as Critical Communications World d... » Critical Communications World (May 16-18, Hong Kong) is the leading and most influential congress an... New initiative shows increasing importance of CSR » A major new survey on corporate social responsibility (CSR) is now open to electrotechnical busine... OF FOOLS OF THE MIDDLE BELT, ONE NORTH AND PASTORA... » SERIES: BUHARISM AND THE FIERCE URGENCY OF NOW A treatise on pastoral jihadism, islamism, arabism a... Commvault partners with Pure Storage » Cisco Live, Melbourne, AU and Tinton Falls, NJ: Commvault has announced the integration of its Commv... OF FOOLS OF THE MIDDLE BELT, ONE NORTH AND PASTOR... » A treatise on pastoral jihadism, islamism, arabism and cultural imperialism in Nigeria (Ephesians ... Where was Aisha Buhari when idiot Kumapayi flagr... » "Clip-clip..clip-clip...Did you not hear when BABA DAURA say women's place is in the kitchen?" ... UKCloud launches Disaster Recovery to the Cloud se... » London: UKCloud has announced the launch of Disaster Recovery to the Cloud, a self-service replicati... ADG Holdings bolsters security protection with Tra... » SAN MATEO, CA : TrapX Security™ has announced that ADG Holdings, a provider of proprietary trading a... ExtraHop combines analytics and low-cost storage... » London, UK: ExtraHop has announced several major platform enhancements as part of version 6.2. These... DEFENCE MINISTER MEETS TEENAGERS TAKING PART ... » Defence Minister Earl Howe today met teenagers at the Army’s first ‘Supercamp’, a new initiative whi...



Health Security Header

LONDON, UK: The UK Department of Health’s rejection of an 800,000-signature public petition to expand the routine administration of the only approved vaccine to offer protection against invasive meningococcal disease (IMD) caused by serogroup B (MenB), may lead to parents and physicians to consider purchasing the vaccine themselves, according to an analyst with research and consulting firm GlobalData.

The decision to keep free access to GlaxoSmithKline’s MenB vaccine, Bexsero, limited to infants rather than vaccinating children up to 11 years of age, as requested in the petition, is a significant setback for the advocacy groups and parents aiming for expanded vaccine administration.

Mirco Junker, Ph.D., GlobalData’s Analyst covering Infectious Diseases, explains: “Even though IMD cases caused by serogroups B and C are most prevalent, the majority of European countries only routinely administer meningococcal vaccines against serogroup C, which provide excellent safety and efficacy profiles in combination with relatively low price points. MenB vaccines, on the other hand, are relatively new and expensive, and there is only limited clinical data demonstrating their long-term effectiveness.

“This uncertainty regarding the long-term efficacy - together with studies indicating low cost-effectiveness of MenB vaccines - also highlights the general conflicts rare diseases like IMD bring up when medical needs are pitted against the commercial viability of vaccines. Indeed, vaccinating entire populations against rare diseases can be extremely challenging to rationalize from a pharmacoeconomic perspective.”

In fact, in 2014, a study using the analysis of quality-adjusted life-years indicated that the new MenB vaccine would not be cost-effective even if provided to the National Health Service (NHS) for less than £1 per dose. However, cost-effectiveness should not be viewed as the main determining factor for the broad application of a vaccine against a rare disease, as many vaccines might not pass this threshold, given low enough disease prevalence.

Junker continues: “While the Department of Health’s decision is a disappointment for parents worried about their children developing IMD, GlobalData believes it is understandable from the perspective of the NHS, as healthcare costs continue to rise and governmental agencies have to balance the restraints of a limited budget with society’s medical needs.

“A reasonable compromise could be to provide individual families concerned about IMD to purchase vaccines out-of-pocket without having to face the list price of the vaccine. As such, it might be in the interest of the pharmaceutical industry to provide incentives to make the vaccine available to individuals not covered under the NHS guidelines.”